Therapeutic strategies aimed at improving neuroplasticity in Alzheimer disease

MF Colavitta, FJ Barrantes - Pharmaceutics, 2023 - mdpi.com
Alzheimer disease (AD) is the most prevalent form of dementia among elderly people.
Owing to its varied and multicausal etiopathology, intervention strategies have been highly …

Molecular factors mediating neural cell plasticity changes in dementia brain diseases

W Kozubski, K Ong, W Waleszczyk, M Zabel… - Neural …, 2021 - Wiley Online Library
Neural plasticity—the ability to alter a neuronal response to environmental stimuli—is an
important factor in learning and memory. Short‐term synaptic plasticity and long‐term …

Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint

G Pepeu - Progress in Neuro-Psychopharmacology and …, 2001 - Elsevier
Drugs effective in Alzheimer's disease (AD) should have several aims: to improve the
cognitive impairment, control the behavioural and neurological symptoms, delay the …

The contribution of transgenic and nontransgenic animal models in Alzheimer's disease drug research and development

E Mhillaj, V Cuomo, C Mancuso - Behavioural pharmacology, 2017 - journals.lww.com
Over the last few years, several papers have become available in the literature on both the
main hallmarks of Alzheimer's disease (AD) and the several intracellular pathways whose …

Alzheimer's disease: Key developments support promising perspectives for therapy

J Meldolesi - Pharmacological research, 2019 - Elsevier
Alzheimer's is the neurodegenerative disease affecting the largest number of patients in the
world. In spite of the intense research of the last decades, progress about its knowledge and …

Therapeutic approaches for the treatment of Alzheimer's disease: an overview

LF Lau, MA Brodney - Alzheimer's Disease, 2008 - Springer
Alzheimer's disease (AD) is a neurodegenerative disease that robs the minds of our elderly
population. Approximately one in every eight adults over the age of 65 and nearly half of …

Alzheimer's therapeutic development: shifting neurodegeneration to neuroregeneration

MK Sun, DL Alkon - Trends in Pharmacological Sciences, 2024 - cell.com
Abstract Alzheimer's disease (AD), similar to AD-related dementias, is characterized by
impaired/lost neuronal structures and functions due to a long progression of …

Opportunities and challenges in developing Alzheimer disease therapeutics

K Iqbal, I Grundke-Iqbal - Acta neuropathologica, 2011 - Springer
Alzheimer disease (AD) is a chronic, progressive disorder with an average disease
progression of 7–10 years. However, the histopathological hallmark lesions of this disease …

Alzheimer's disease: new prospects in therapy and applied experimental models

AM Kubis, M Janusz - Postepy Higieny i Medycyny Doswiadczalnej …, 2008 - europepmc.org
Neurodegenerative disorders such as Alzheimer's disease (AD) are the most common
disease of modern society. The gradual and irreversible disturbances in homeostasis are …

Drugs in clinical trials for Alzheimer's disease: the major trends

SO Bachurin, EV Bovina… - Medicinal research …, 2017 - Wiley Online Library
Alzheimer's disease (AD) is characterized by a chronic and progressive neurodegenerative
process resulting from the intracellular and extracellular accumulation of fibrillary proteins …